Madrid

• Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM). Ended
  2024-516808-42-00 4 2022-08-18 Effect of loratadine in patients with lymphangioleiomyomatosis
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors Ended
  2023-505425-14-00 9 2022-08-11 colorectal cancer
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect … Ended
  2023-503797-21-00 5 2022-08-10 Metastatic Colorectal Cancer
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or … Ended
  2023-504257-12-00 4 2022-07-28 Portal hypertension
• Two-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended
  2024-511069-12-00 5 2022-07-28 Sjögren’s Syndrome
• A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian … Ended
  2023-505005-16-00 4 2022-07-27 Primary peritoneal cancer/Fallopian tube cancer
• A Study of HFB301001 in Adult Patients With Advanced Solid Tumors Ended
  2023-506402-39-00 1 2022-07-27 Advanced cancer of different organs
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC). Ended
  2023-509095-42-00 4 2022-07-14 Colorectal cancer
• Study of RP2 alone and in combination with PD1 Blockade in patients with solid tumours Ended
  2024-512866-32-00 7 2022-07-12 Solid tumors
• Study in Paediatrics with HypEREosinophilic syndrome (SPHERE) Ended
  2023-510110-36-00 5 2022-07-11 Hypereosinophilic syndrome (HES)
• Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advance … Ended
  2024-514293-46-00 4 2022-07-07 Unresectable locally advanced or metastatic urothelial cancer
• Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th … Ended
  2024-515485-14-00 5 2022-07-07 Acute major bleeding in patients receiving DOAC therapy with factor Xa
• A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington’s D … Ended
  2023-509835-26-00 4 2022-07-06 Huntington’s Disease
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 10 2022-06-30 Pulmonary Arterial Hypertension (PAH)
• Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) Ended
  2023-504441-31-00 7 2022-06-29 gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junct
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 Solid tumours
• Treprostinil Palmitil Inhalation Powder for Pulmonary Arterial Hypertension Ended
  2023-505541-99-00 4 2022-06-28 Pulmonary Arterial Hypertension
• A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination … Ended
  2024-511744-27-00 1 2022-06-27 Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial
• A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a C … Ended
  2024-514532-24-00 3 2022-06-23 Solid cancer tumors
• Phase 2 Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial I … Ended
  2023-507569-24-00 4 2022-06-20 Myocardial Infarction, Acute Heart Failure, Left Sided
• A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination … Ended
  2024-511352-41-00 3 2022-06-13 advanced solid tumors

Showing 3,121–3,144 of 3,550 trials